The p53/mouse double minute 2 homolog complex deregulation in merlin-deficient tumours

Molecular Oncology

Volumn 9, Issue 1, 2015, Pages 236-248

  Ammoun, Sylwia ^a   Schmid, Marei Caroline ^a   Zhou, Lu ^a   Hilton, David A ^b   Barczyk, Magdalena ^a   Hanemann, Clemens Oliver ^a  

^a PLYMOUTH UNIVERSITY PENINSULA SCHOOLS OF MEDICINE AND DENTISTRY   (United Kingdom)

^b DERRIFORD HOSPITAL   (United Kingdom)

Author keywords

FAK; Merlin; Neurofibromatosis type 2 (NF2); P53 MDM2; Proliferation and survival

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; MERLIN; NUTLIN 3; PROTEIN KINASE B; PROTEIN MDM2; PROTEIN P53; WORTMANNIN; FOCAL ADHESION KINASE 1; MDM2 PROTEIN, HUMAN; MULTIPROTEIN COMPLEX; PHOSPHATIDYLINOSITOL 3 KINASE; PTK2 PROTEIN, HUMAN; TP53 PROTEIN, HUMAN;

ARTICLE; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOBLOTTING; IMMUNOCYTOCHEMISTRY; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; NEOPLASM; NEURILEMOMA; PROTEIN DEFICIENCY; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN STABILITY; PROTEIN SYNTHESIS; SCHWANN CELL; TUMOR CELL; TUMOR GROWTH; UPREGULATION; WESTERN BLOTTING; DEFICIENCY; GENETICS; METABOLISM; PATHOLOGY;

FOCAL ADHESION KINASE 1; HUMANS; MULTIPROTEIN COMPLEXES; NEURILEMMOMA; NEUROFIBROMIN 2; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84920605700     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2014.08.005     Document Type: Article

References (47)

1. Alvarez-Moya B., Lopez-Alcala C., Drosten M., Bachs O., Agell N. K-Ras4B phosphorylation at Ser181 is inhibited by calmodulin and modulates K-Ras activity and function. Oncogene 2010, 29:5911-5922.
2. Ammoun S., Cunliffe C.H., Allen J.C., Chiriboga L., Giancotti F.G., Zagzag D., Hanemann C.O., Karajannis M.A. ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma. Neuro Oncol. 2010, 12:834-843.
3. Ammoun S., Flaiz C., Ristic N., Schuldt J., Hanemann C.O. Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma. Cancer Res. 2008, 68:5236-5245.
4. Ammoun S., Provenzano L., Zhou L., Barczyk M., Evans K., Hilton D.A., Hafizi S., Hanemann C.O. Axl/Gas6/NFkappaB signalling in schwannoma pathological proliferation, adhesion and survival. Oncogene 2014, 33:336-346.
5. Ammoun S., Schmid M.C., Ristic N., Zhou L., Hilton D., Ercolano E., Carroll C., Hanemann C.O. The role of insulin-like growth factors signaling in merlin-deficient human schwannomas. GLIA 2012, 60:1721-1733.
6. Ammoun S., Schmid M.C., Triner J., Manley P., Hanemann C.O. Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2. Neuro Oncol. 2011, 13:759-766.
7. Ammoun S., Schmid M.C., Zhou L., Ristic N., Ercolano E., Hilton D.A., Perks C.M., Hanemann C.O. Insulin-like growth factor-binding protein-1 (IGFBP-1) regulates human schwannoma proliferation, adhesion and survival. Oncogene 2011, 31.
8. Blakeley J.O., Evans D.G., Adler J., Brackmann D., Chen R., Ferner R.E., Hanemann C.O., Harris G., Huson S.M., Jacob A., Kalamarides M., Karajannis M.A., Korf B.R., Mautner V.F., McClatchey A.I., Miao H., Plotkin S.R., Slattery W., Stemmer-Rachamimov A.O., Welling D.B., Wen P.Y., Widemann B., Hunter-Schaedle K., Giovannini M. Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2. Am. J. Med. Genet. A 2012, 158A:24-41.
9. Chen H., Mei L., Zhou L., Zhang X., Guo C., Li J., Wang H., Zhu Y., Zheng Y., Huang L. Moesin-ezrin-radixin-like protein (merlin) mediates protein interacting with the carboxyl terminus-1 (PICT-1)-induced growth inhibition of glioblastoma cells in the nucleus. Int. J. Biochem. Cell Biol. 2011, 43:545-555.
10. Chylicki K., Ehinger M., Svedberg H., Bergh G., Olsson I., Gullberg U. p53-mediated differentiation of the erythroleukemia cell line K562. Cell growth & differentiation. Mol. Biol. J. Am. Assoc. Cancer Res. 2000, 11:315-324.
11. Chylicki K., Ehinger M., Svedberg H., Gullberg U. Characterization of the molecular mechanisms for p53-mediated differentiation. Cell growth & differentiation. Mol. Biol. J. Am. Assoc. Cancer Res. 2000, 11:561-571.
12. Flaiz C., Kaempchen K., Matthies C., Hanemann C.O. Actin-rich protrusions and nonlocalized GTPase activation in merlin-deficient schwannomas. J. Neuropathol. Exp. Neurol. 2007, 66:608-616.
13. Fuchs S.Y., Adler V., Pincus M.R., Ronai Z. MEKK1/JNK signaling stabilizes and activates p53. Proc. Natl. Acad. Sci. U S A 1998, 95:10541-10546.
14. Gajjar M., Candeias M.M., Malbert-Colas L., Mazars A., Fujita J., Olivares-Illana V., Fahraeus R. The p53 mRNA-Mdm2 interaction controls Mdm2 nuclear trafficking and is required for p53 activation following DNA damage. Cancer Cell 2012, 21:25-35.
15. Hanemann C.O., Bartelt-Kirbach B., Diebold R., Kampchen K., Langmesser S., Utermark T. Differential gene expression between human schwannoma and control Schwann cells. Neuropathol. Appl. Neurobiol. 2006, 32:605-614.
16. Hennessy B.T., Smith D.L., Ram P.T., Lu Y., Mills G.B. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nature Rev. Drug Discovery 2005, 4:988-1004.
17. Higami Y., Shimokawa I., Kishikawa M., Okimoto T., Ohtani H., Tomita M., Tsujino A., Ikeda T. Malignant peripheral nerve sheath tumors developing multifocally in the central nervous system in a patient with neurofibromatosis type 2. Clin. Neuropathol. 1998, 17:115-120.
18. Horn H.F., Vousden K.H. Coping with stress: multiple ways to activate p53. Oncogene 2007, 26:1306-1316.
19. Kaempchen K., Mielke K., Utermark T., Langmesser S., Hanemann C.O. Upregulation of the Rac1/JNK signaling pathway in primary human schwannoma cells. Hum. Mol. Genet. 2003, 12:1211-1221.
20. Kim H., Kwak N.J., Lee J.Y., Choi B.H., Lim Y., Ko Y.J., Kim Y.H., Huh P.W., Lee K.H., Rha H.K., Wang Y.P. Merlin neutralizes the inhibitory effect of Mdm2 on p53. J.Biol. Chem. 2004, 279:7812-7818.
21. Lev Bar-Or R., Maya R., Segel L.A., Alon U., Levine A.J., Oren M. Generation of oscillations by the p53-Mdm2 feedback loop: a theoretical and experimental study. Proc. Natl. Acad. Sci. U S A 2000, 97:11250-11255.
22. Li Q., Lozano G. Molecular pathways: targeting Mdm2 and Mdm4 in cancer therapy. Clin. Cancer Res. 2013, 19:34-41.
23. Li W., You L., Cooper J., Schiavon G., Pepe-Caprio A., Zhou L., Ishii R., Giovannini M., Hanemann C.O., Long S.B., Erdjument-Bromage H., Zhou P., Tempst P., Giancotti F.G. Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus. Cell 2010, 140:477-490.
24. Lim S.T., Chen X.L., Lim Y., Hanson D.A., Vo T.T., Howerton K., Larocque N., Fisher S.J., Schlaepfer D.D., Ilic D. Nuclear FAK promotes cell proliferation and survival through FERM-enhanced p53 degradation. Mol. Cell 2008, 29:9-22.
25. Luo J., Manning B.D., Cantley L.C. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 2003, 4:257-262.
26. Mayo L.D., Donner D.B. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc. Natl. Acad. Sci. U S A 2001, 98:11598-11603.
27. Mayo L.D., Donner D.B. The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network. Trends Biochem. Sci. 2002, 27:462-467.
28. McClatchey A.I., Giovannini M. Membrane organization and tumorigenesis-the NF2 tumor suppressor. Merlin. Genes Dev. 2005, 19:2265-2277.
29. Morrow K.A., Das S., Metge B.J., Ye K., Mulekar M.S., Tucker J.A., Samant R.S., Shevde L.A. Loss of tumor suppressor Merlin in advanced breast cancer is due to post-translational regulation. J.Biol. Chem. 2011, 286:40376-40385.
30. Muller P.A., Vousden K.H., Norman J.C. p53 and its mutants in tumor cell migration and invasion. J.Cell Biol. 2011, 192:209-218.
31. Olivier M., Hollstein M., Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb. Perspect. Biol. 2010, 2:a001008.
32. Ouhtit A., Muller H.K., Davis D.W., Ullrich S.E., McConkey D., Ananthaswamy H.N. Temporal events in skin injury and the early adaptive responses in ultraviolet-irradiated mouse skin. Am. J. Pathol. 2000, 156:201-207.
33. Ponnuswamy A., Hupp T., Fahraeus R. Concepts in MDM2 signaling: allosteric regulation and feedback loops. Genes Cancer 2012, 3:291-297.
34. Poulikakos P.I., Xiao G.H., Gallagher R., Jablonski S., Jhanwar S.C., Testa J.R. Re-expression of the tumor suppressor NF2/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK. Oncogene 2006.
35. Reiske H.R., Kao S.C., Cary L.A., Guan J.L., Lai J.F., Chen H.C. Requirement of phosphatidylinositol 3-kinase in focal adhesion kinase-promoted cell migration. J. Biol. Chem. 1999, 274:12361-12366.
36. Rosenbaum C., Kamleiter M., Grafe P., Kluwe L., Mautner V., Muller H.W., Hanemann C.O. Enhanced proliferation and potassium conductance of Schwann cells isolated from NF2 schwannomas can be reduced by quinidine. Neurobiol. Dis. 2000, 7:483-491.
37. Sandrini J.Z., Trindade G.S., Nery L.E., Marins L.F. Time-course expression of DNA repair-related genes in hepatocytes of zebrafish (Danio rerio) after UV-B exposure. Photochem. Photobiol. 2009, 85:220-226.
38. Singh S., Ramamoorthy M., Vaughan C., Yeudall W.A., Deb S., Palit Deb S. Human oncoprotein MDM2 activates the Akt signaling pathway through an interaction with the repressor element-1 silencing transcription factor conferring a survival advantage to cancer cells. Cell Death Differ. 2013, 20:558-566.
39. Utermark T., Kaempchen K., Antoniadis G., Hanemann C.O. Reduced apoptosis rates in human schwannomas. Brain Pathol. 2005, 15:17-22.
40. Utermark T., Kaempchen K., Hanemann C.O. Pathological adhesion of primary human schwannoma cells is dependent on altered expression of integrins. Brain Pathol. 2003, 13:352-363.
41. Vogelstein B., Lane D., Levine A.J. Surfing the p53 network. Nature 2000, 408:307-310.
42. Walerych D., Napoli M., Collavin L., Del Sal G. The rebel angel: mutant p53 as the driving oncogene in breast cancer. Carcinogenesis 2012, 33:2007-2017.
43. Wu L., Levine A.J. Differential regulation of the p21/WAF-1 and mdm2 genes after high-dose UV irradiation: p53-dependent and p53-independent regulation of the mdm2 gene. Mol. Med. 1997, 3:441-451.
44. Xiao G.H., Gallagher R., Shetler J., Skele K., Altomare D.A., Pestell R.G., Jhanwar S., Testa J.R. The NF2 tumor suppressor gene product, merlin, inhibits cell proliferation and cell cycle progression by repressing cyclin D1 expression. Mol. Cell. Biol. 2005, 25:2384-2394.
45. Zhang W., McQueen T., Schober W., Rassidakis G., Andreeff M., Konopleva M. Leukotriene B4 receptor inhibitor LY293111 induces cell cycle arrest and apoptosis in human anaplastic large-cell lymphoma cells via JNK phosphorylation. Leukemia 2005, 19:1977-1984.
46. Zhou B.P., Liao Y., Xia W., Zou Y., Spohn B., Hung M.C. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat. Cell Biol. 2001, 3:973-982.
47. Zhou L., Ercolano E., Ammoun S., Schmid M.C., Barczyk M.A., Hanemann C.O. Merlin-deficient human tumors show loss of contact inhibition and activation of Wnt/beta-catenin signaling linked to the PDGFR/Src and Rac/PAK pathways. Neoplasia 2011, 13:1101-1112.